Mifepristone (RU-486) in Androgen Independent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

January 31, 2008

Conditions
Prostate CancerAdenocarcinoma of Prostate
Interventions
DRUG

Mifepristone

200mg orally once daily

Trial Locations (4)

20057

Georgetown University, Washington D.C.

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Georgetown University

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00140478 - Mifepristone (RU-486) in Androgen Independent Prostate Cancer | Biotech Hunter | Biotech Hunter